Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

11.80USD
17 Nov 2017
Change (% chg)

$0.65 (+5.83%)
Prev Close
$11.15
Open
$11.20
Day's High
$11.95
Day's Low
$11.20
Volume
145,615
Avg. Vol
129,645
52-wk High
$17.20
52-wk Low
$9.90

Select another date:

Fri, Nov 3 2017

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed‍​

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing ‍​ Source text: http://bit.ly/2hauCBo Further company coverage:

BRIEF-Cytokinetics enters into second amendment to certain loan and security agreement

* Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015

BRIEF-Cytokinetics reports Q3 loss of ‍$0.60/shr​

* Cytokinetics, Inc. reports third quarter 2017 financial results

BRIEF-Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

* Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

BRIEF-Cytokinetics announces additional results from COSMIC-HF at HFSA 21st Annual Scientific Meeting

* Cytokinetics announces presentation of additional results from COSMIC-HF at the HFSA 21st Annual Scientific Meeting Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics Q2 loss per share $0.60

* Cytokinetics Inc reports second quarter 2017 financial results

BRIEF-Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil

* Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure

BRIEF-Cytokinetics announces start of FORTITUDE-ALS

* Cytokinetics announces start of fortitude-als, a phase 2 clinical trial of ck-2127107 in patients with amyotrophic lateral sclerosis Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA

* Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma

BRIEF-Cytokinetics starts phase 1B clinical trial of CK-2127107 in elderly subjects

* Cytokinetics announces start of phase 1B clinical trial of CK-2127107 in elderly subjects with limited mobility

Select another date: